Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

268.23
Delayed Data
As of Sep 25
 +5.10 / +1.94%
Today’s Change
165.23
Today|||52-Week Range
306.08
+22.51%
Year-to-Date
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status
Sep 23 / Zacks.com - Paid Partner Content
European advisory group backs expanded use of Vertex's Kalydeco
Sep 18 / Seeking Alpha - Paid Partner Content
Stock Market Crash 2.0: Where to Invest $1,000
Sep 23 / MotleyFool.com - Paid Partner Content
Beyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis Therapy
Sep 17 / MotleyFool.com - Paid Partner Content
3 High-Growth Value Stocks Robinhood Investors Can Buy Right Now
Sep 22 / MotleyFool.com - Paid Partner Content
Why Moderna Was So Volatile on Thursday
Sep 17 / MotleyFool.com - Paid Partner Content
Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should Know
Sep 21 / Zacks.com - Paid Partner Content
Wall Street Breakfast: Fed Reaction
Sep 17 / Seeking Alpha - Paid Partner Content
Crispr: The Frontier Of Gene Editing
Sep 18 / Seeking Alpha - Paid Partner Content
Stock Market Crash 2.0: Here Are 3 Stocks You'll Absolutely, Positively Want to Buy
Sep 17 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close263.13
Today’s open262.96
Day’s range260.54 - 268.89
Volume64,044
Average volume (3 months)1,529,278
Market cap$69.1B
Data as of 3:59pm ET, 09/25/2020

Growth & Valuation

Earnings growth (last year)-44.37%
Earnings growth (this year)+82.50%
Earnings growth (next 5 years)+46.50%
Revenue growth (last year)+35.47%
P/E ratio33.9
Price/Sales13.82
Price/Book11.30

Competitors

----
ZTSZoetis Inc+2.86+1.81%
----
REGNRegeneron Pharmaceut...+17.04+3.06%
Data as of 4:00pm ET, 09/25/2020

Financials

Next reporting dateOctober 21, 2020
EPS forecast (this quarter)$2.28
Annual revenue (last year)$4.1B
Annual profit (last year)$1.2B
Net profit margin28.49%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Boston, Massachusetts

Forecasts